Bicycle therapeutics announces proposed $200 million public offering of american depositary shares and non-voting ordinary shares

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced that it has commenced an underwritten public offering of $200 million of american depositary shares (“adss”), each representing one ordinary share and, in lieu of adss to investors that so choose, non-voting ordinary shares. all of the adss and non-.
BCYC Ratings Summary
BCYC Quant Ranking